Advocating for Patients: Letter to the FDA on RP1 Treatment Access
Published:
09/05/2025
Categories:
Hundreds of patients, families, and friends have shared their stories with AIM at Melanoma about the urgent need for access to RP1+nivolumab. We are grateful to everyone who contributed. Yesterday, along with several other melanoma organizations, we sent a letter to the FDA urging them to make RP1 available while remaining regulatory issues are addressed.
The full letter is embedded below for your reference. Click on the image to enlarge it, or download the PDF using the link beneath the letter.
Recent Posts
Feb. 05, 2026
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
Jan. 23, 2026
Moderna, Merck’s Skin Cancer Vaccine Shows Sustained Benefit in Five-Year Follow-Up
Jan. 21, 2026
Reflecting on Melanoma Treatment in 2025 and Looking to the Future in 2026
Jan. 13, 2026
The Integrative Care Approach
Jan. 13, 2026